Health & Fitness
Mon, July 18, 2011Fri, July 15, 2011Thu, July 14, 2011Wed, July 13, 2011Tue, July 12, 2011Mon, July 11, 2011Sun, July 10, 2011Sat, July 9, 2011Fri, July 8, 2011Thu, July 7, 2011Wed, July 6, 2011Tue, July 5, 2011Mon, July 4, 2011Sat, July 2, 2011Fri, July 1, 2011Thu, June 30, 2011Wed, June 29, 2011Tue, June 28, 2011Mon, June 27, 2011Sat, June 25, 2011Fri, June 24, 2011Thu, June 23, 2011Wed, June 22, 2011Robbins Umeda LLP Announces an Investigation of Immucor, Inc.
Published in Health and Fitness on Tuesday, July 5th 2011 at 19:20 GMT by Market Wire
SAN DIEGO--([ BUSINESS WIRE ])--Robbins Umeda LLP, a [ shareholder rights litigation ] firm, is interested in helping shareholders of Immucor, Inc. (NASDAQ: BLUD). The firm has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the board of directors of Immucor in connection with their efforts to sell the company to funds managed by TPG Capital.
If you own stock in Immucor and would like more information about your [ shareholder rights ], please contact Gregory E. Del Gaizo at 800-350-6003 or via the [ shareholder information form ] on our website.
On July 5, 2011, Immucor announced it had entered into a definitive merger agreement under which TPG Capital will acquire all outstanding shares of the company via an all cash tender offer. Under the terms of the agreement, no later than July 15, 2011, IVD Acquisition Corporation, an affiliate of TPG Capital, is expected to commence a tender offer to acquire all outstanding shares of Immucor for $27.00 per share. The transaction is expected to close in the second half of 2011.
The investigation focuses on whether Immucor's board is undertaking a fair process to obtain maximum value and adequately compensate its shareholders in light of the company's recent positive financial results. On April 6, 2011, Immucor reported strong third-quarter earnings that greatly exceeded analyst expectations. The company reported a diluted EPS of $0.32 and $83.30 million in revenue for the quarter. These results beat analyst estimates of an EPS of $0.26 and revenue of $79.77 million for the same period. Taken together, Immucor's revenue figures for the quarter represented a 4% increase from the prior year quarter.
Robbins Umeda LLP represents individual and institutional shareholders in derivative, direct, and class action lawsuits. Robbins Umeda LLP has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. The firm's skilled litigation teams include former federal prosecutors, former defense counsel from top multinational corporate law firms, and career [ shareholder rights attorneys ]. For more information, please go to [ http://www.robbinsumeda.com ].
Press release link: [ http://www.robbinsumeda.com/shareholders-rights-blog/immucor-inc/ ]
Attorney Advertising. Past results do not guarantee a similar outcome.
